You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameLevobunolol
Accession NumberDB01210  (APRD00165)
TypeSmall Molecule
GroupsApproved
DescriptionA nonselective beta-adrenoceptor antagonist used in the treatment of glaucoma. [PubChem]
Structure
Thumb
Synonyms
(-)-Bunolol
(S)-5-(3-((1,1-Dimethylethyl)amino)-2-hydroxypropoxy)-3,4-dihydro-1(2H)-naphthalenone
Levobunolol
Levobunololum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
BetaganSolution / drops5 mg/mLOphthalmicAllergan, Inc.1986-07-24Not applicableUs
Betagan 0.5% Ophthalmic SolLiquid5 mgOphthalmicAllergan Inc1985-12-31Not applicableCanada
Betagan Oph Soln 0.25%Liquid0.25 %OphthalmicAllergan Inc1990-12-31Not applicableCanada
Levobunolol HydrochlorideSolution / drops5 mg/mLOphthalmicPacific Pharma, Inc.1997-07-15Not applicableUs
Levobunolol Hydrochloride Ophthalmic SolutionLiquid0.25 %OphthalmicBausch & Lomb Pharmaceuticals Inc.1997-09-242003-07-14Canada
Levobunolol Hydrochloride Ophthalmic SolutionLiquid0.50 %OphthalmicBausch & Lomb Pharmaceuticals Inc.1997-09-242003-07-14Canada
Levobunolol Hydrochloride Ophthalmic SolutionLiquid0.25 %OphthalmicAlcon Canada IncNot applicableNot applicableCanada
Levobunolol Hydrochloride Ophthalmic SolutionLiquid0.50 %OphthalmicAlcon Canada IncNot applicableNot applicableCanada
Novo-levobunolol - Liq 0.25%Liquid0.25 %OphthalmicNovopharm Limited1996-07-302015-10-26Canada
Novo-levobunolol - Liq 0.5%Liquid0.5 %OphthalmicNovopharm Limited1996-07-302015-10-26Canada
PMS-levobunololLiquid0.5 %OphthalmicPharmascience Inc1998-08-312016-10-28Canada
PMS-levobunololLiquid0.25 %OphthalmicPharmascience IncNot applicableNot applicableCanada
Ratio-levobunololSolution0.25 %OphthalmicTeva Canada Limited1995-12-31Not applicableCanada
Ratio-levobunololSolution0.5 %OphthalmicTeva Canada Limited1995-12-31Not applicableCanada
Sandoz LevobunololLiquid0.25 %OphthalmicSandoz Canada Incorporated2000-08-21Not applicableCanada
Sandoz LevobunololLiquid0.5 %OphthalmicSandoz Canada Incorporated2000-08-21Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-levobunolol Ophthalmic Solution USP 0.25%Liquid0.25 %OphthalmicApotex Inc2000-02-21Not applicableCanada
Apo-levobunolol Ophthalmic Solution USP 0.5%Liquid0.5 %OphthalmicApotex Inc2000-02-21Not applicableCanada
Levobunolol HydrochlorideSolution / drops2.5 mg/mLOphthalmicBausch & Lomb Incorporated1994-03-042016-10-13Us
Levobunolol HydrochlorideSolution / drops5 mg/mLOphthalmicPhysicians Total Care, Inc.1995-02-23Not applicableUs
Levobunolol HydrochlorideSolution / drops5 mg/mLOphthalmicBausch & Lomb Incorporated1994-03-04Not applicableUs
Levobunolol HydrochlorideSolution5 mg/mLOphthalmicSandoz Inc1997-01-30Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AkbetaNot Available
Brand mixtures
NameLabellerIngredients
Probeta - Liq OphAllergan Inc
Salts
Name/CASStructureProperties
Levobunolol Hydrochloride
27912-14-7
Thumb
  • InChI Key: DNTDOBSIBZKFCP-YDALLXLXSA-N
  • Monoisotopic Mass: 327.16012141
  • Average Mass: 327.846
DBSALT000251
Categories
UNIIG6317AOI7K
CAS number47141-42-4
WeightAverage: 291.3853
Monoisotopic: 291.183443671
Chemical FormulaC17H25NO3
InChI KeyIXHBTMCLRNMKHZ-LBPRGKRZSA-N
InChI
InChI=1S/C17H25NO3/c1-17(2,3)18-10-12(19)11-21-16-9-5-6-13-14(16)7-4-8-15(13)20/h5-6,9,12,18-19H,4,7-8,10-11H2,1-3H3/t12-/m0/s1
IUPAC Name
5-[(2S)-3-(tert-butylamino)-2-hydroxypropoxy]-1,2,3,4-tetrahydronaphthalen-1-one
SMILES
CC(C)(C)NC[[email protected]](O)COC1=CC=CC2=C1CCCC2=O
Pharmacology
IndicationFor lowering intraocular pressure (IOP) and may be used in patients with chronic open-angle glaucoma or ocular hypertension.
Structured Indications
PharmacodynamicsLevobunolol is an ophthalmic beta-blocker, equally effective at β(1)- and β(2)-receptor sites. Levobunolol reduces both elevated and normal IOP in patients with or without glaucoma. In patients with elevated IOP, levobunolol reduces mean IOP by approximately 25-40% from baseline. As the drug is a nonselective &beta-adrenergic blocking agent, it can produce both systemic pulmonary and cardiovascular effects following topical application to the eye. These effects include adverse pulmonary effects (eg. bronchoconstriction, increased airway resistance), and a decrease in blood pressure and heart rate.
Mechanism of actionLevobunolol's mechanism of action in reducing IOP is not clearly defined, but is believed to be due to a reduction of the production of aqueous humor via blockage of endogenous catecholamine-stimulated increases in cyclic adenosine monophosphate (AMP) concentrations within the ciliary processes.
TargetKindPharmacological actionActionsOrganismUniProt ID
Beta-1 adrenergic receptorProteinyes
antagonist
HumanP08588 details
Beta-2 adrenergic receptorProteinyes
antagonist
HumanP07550 details
Related Articles
Absorption80%
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Hepatic

Route of eliminationNot Available
Half life20 hours
ClearanceNot Available
ToxicityBradycardia, hypotension, bronchospasm, and acute cardiac failure, LD50=700 mg/kg (orally in rat).
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Levobunolol Action PathwayDrug actionSMP00666
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,10-Phenanthroline1,10-Phenanthroline may increase the bradycardic activities of Levobunolol.Experimental
AcebutololThe risk or severity of adverse effects can be increased when Acebutolol is combined with Levobunolol.Approved
AceclofenacAceclofenac may decrease the antihypertensive activities of Levobunolol.Approved
AcepromazineAcepromazine may increase the hypotensive activities of Levobunolol.Approved, Vet Approved
AceprometazineAceprometazine may increase the hypotensive activities of Levobunolol.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Levobunolol is combined with Acetazolamide.Approved, Vet Approved
AcetohexamideLevobunolol may increase the hypoglycemic activities of Acetohexamide.Withdrawn
AcetovanilloneAcetovanillone may decrease the antihypertensive activities of Levobunolol.Investigational
AcetylcholineThe risk or severity of adverse effects can be increased when Levobunolol is combined with Acetylcholine.Approved
AcetyldigitoxinLevobunolol may increase the bradycardic activities of Acetyldigitoxin.Approved
Acetylsalicylic acidAcetylsalicylic acid may decrease the antihypertensive activities of Levobunolol.Approved, Vet Approved
AdapaleneAdapalene may decrease the antihypertensive activities of Levobunolol.Approved
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Levobunolol.Approved
AlfentanilAlfentanil may increase the bradycardic activities of Levobunolol.Approved, Illicit
AlimemazineAlimemazine may increase the hypotensive activities of Levobunolol.Approved, Vet Approved
AliskirenThe risk or severity of adverse effects can be increased when Levobunolol is combined with Aliskiren.Approved, Investigational
AmbenoniumAmbenonium may increase the bradycardic activities of Levobunolol.Approved
AmifostineThe risk or severity of adverse effects can be increased when Levobunolol is combined with Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Levobunolol.Approved
AmiodaroneAmiodarone may increase the bradycardic activities of Levobunolol.Approved, Investigational
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Levobunolol.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Levobunolol.Approved, Illicit
AmodiaquineThe metabolism of Levobunolol can be decreased when combined with Amodiaquine.Approved
Amphotericin BThe risk or severity of adverse effects can be increased when Levobunolol is combined with Amphotericin B.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Levobunolol is combined with Amyl Nitrite.Approved
AnisodamineAnisodamine may decrease the antihypertensive activities of Levobunolol.Investigational
AntipyrineAntipyrine may decrease the antihypertensive activities of Levobunolol.Approved
AnvirzelLevobunolol may increase the bradycardic activities of Anvirzel.Investigational
ApomorphineThe risk or severity of adverse effects can be increased when Levobunolol is combined with Apomorphine.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Apraclonidine is combined with Levobunolol.Approved
ApremilastApremilast may decrease the antihypertensive activities of Levobunolol.Approved, Investigational
ArecolineThe risk or severity of adverse effects can be increased when Levobunolol is combined with Arecoline.Experimental
AripiprazoleAripiprazole may increase the hypotensive activities of Levobunolol.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Levobunolol is combined with Arotinolol.Approved
Arsenic trioxideThe risk or severity of adverse effects can be increased when Levobunolol is combined with Arsenic trioxide.Approved, Investigational
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Levobunolol.Approved
AzapropazoneAzapropazone may decrease the antihypertensive activities of Levobunolol.Withdrawn
AzelastineAzelastine may decrease the antihypertensive activities of Levobunolol.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Levobunolol is combined with Azilsartan medoxomil.Approved
BalsalazideBalsalazide may decrease the antihypertensive activities of Levobunolol.Approved, Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Levobunolol.Experimental
BarbitalBarbital may increase the hypotensive activities of Levobunolol.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Levobunolol is combined with Barnidipine.Approved
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Levobunolol.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Levobunolol.Approved
BenoxaprofenBenoxaprofen may decrease the antihypertensive activities of Levobunolol.Withdrawn
BepridilThe risk or severity of adverse effects can be increased when Levobunolol is combined with Bepridil.Approved, Withdrawn
BeractantLevobunolol may increase the bradycardic activities of Beractant.Approved
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Levobunolol.Approved
BethanecholThe risk or severity of adverse effects can be increased when Levobunolol is combined with Bethanechol.Approved
Betulinic AcidBetulinic Acid may decrease the antihypertensive activities of Levobunolol.Investigational
BisoprololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Levobunolol.Approved
BL-1020BL-1020 may increase the hypotensive activities of Levobunolol.Investigational
BortezomibThe risk or severity of adverse effects can be increased when Levobunolol is combined with Bortezomib.Approved, Investigational
BretyliumBretylium may increase the bradycardic activities of Levobunolol.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Levobunolol.Approved
BromfenacBromfenac may decrease the antihypertensive activities of Levobunolol.Approved
BromocriptineLevobunolol may increase the vasoconstricting activities of Bromocriptine.Approved, Investigational
BucillamineBucillamine may decrease the antihypertensive activities of Levobunolol.Investigational
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Levobunolol.Approved
BupivacaineThe serum concentration of Bupivacaine can be increased when it is combined with Levobunolol.Approved, Investigational
CabergolineLevobunolol may increase the vasoconstricting activities of Cabergoline.Approved
CalfactantLevobunolol may increase the bradycardic activities of Calfactant.Approved
CanagliflozinThe risk or severity of adverse effects can be increased when Levobunolol is combined with Canagliflozin.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Levobunolol.Approved
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Levobunolol.Approved
CarbacholThe risk or severity of adverse effects can be increased when Levobunolol is combined with Carbachol.Approved
CarbetocinThe risk or severity of adverse effects can be increased when Levobunolol is combined with Carbetocin.Approved
CarprofenCarprofen may decrease the antihypertensive activities of Levobunolol.Approved, Vet Approved, Withdrawn
CarteololThe risk or severity of adverse effects can be increased when Carteolol is combined with Levobunolol.Approved
CarvedilolThe risk or severity of adverse effects can be increased when Carvedilol is combined with Levobunolol.Approved, Investigational
CastanospermineCastanospermine may decrease the antihypertensive activities of Levobunolol.Experimental
CelecoxibCelecoxib may decrease the antihypertensive activities of Levobunolol.Approved, Investigational
CeritinibLevobunolol may increase the bradycardic activities of Ceritinib.Approved
CevimelineThe risk or severity of adverse effects can be increased when Levobunolol is combined with Cevimeline.Approved
ChloroquineThe metabolism of Levobunolol can be decreased when combined with Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Levobunolol.Approved, Vet Approved
ChlorpromazineChlorpromazine may increase the hypotensive activities of Levobunolol.Approved, Vet Approved
ChlorpropamideLevobunolol may increase the hypoglycemic activities of Chlorpropamide.Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Levobunolol.Approved
CilazaprilThe risk or severity of adverse effects can be increased when Levobunolol is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Levobunolol is combined with Cilnidipine.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Levobunolol is combined with Clevidipine.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Levobunolol is combined with Clofarabine.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Levobunolol is combined with Clomipramine.Approved, Vet Approved
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Levobunolol.Approved
ClonixinClonixin may decrease the antihypertensive activities of Levobunolol.Approved
ClozapineThe risk or severity of adverse effects can be increased when Levobunolol is combined with Clozapine.Approved
ConivaptanThe risk or severity of adverse effects can be increased when Levobunolol is combined with Conivaptan.Approved, Investigational
CoumaphosCoumaphos may increase the bradycardic activities of Levobunolol.Vet Approved
CrizotinibLevobunolol may increase the bradycardic activities of Crizotinib.Approved
CurcuminCurcumin may decrease the antihypertensive activities of Levobunolol.Investigational
D-LimoneneD-Limonene may decrease the antihypertensive activities of Levobunolol.Investigational
DapagliflozinThe risk or severity of adverse effects can be increased when Levobunolol is combined with Dapagliflozin.Approved
DapoxetineThe serum concentration of Levobunolol can be increased when it is combined with Dapoxetine.Investigational
DecamethoniumDecamethonium may increase the bradycardic activities of Levobunolol.Approved
DemecariumDemecarium may increase the bradycardic activities of Levobunolol.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Levobunolol is combined with Desflurane.Approved
DeslanosideLevobunolol may increase the bradycardic activities of Deslanoside.Approved
DesvenlafaxineThe serum concentration of Levobunolol can be increased when it is combined with Desvenlafaxine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Levobunolol.Approved, Vet Approved
DichlorvosDichlorvos may increase the bradycardic activities of Levobunolol.Vet Approved
DiclofenacDiclofenac may decrease the antihypertensive activities of Levobunolol.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Levobunolol.Approved
DiflunisalDiflunisal may decrease the antihypertensive activities of Levobunolol.Approved
DigitoxinLevobunolol may increase the bradycardic activities of Digitoxin.Approved
DigoxinDigoxin may increase the bradycardic activities of Levobunolol.Approved
DihydroergotamineLevobunolol may increase the vasoconstricting activities of Dihydroergotamine.Approved
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Levobunolol.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Levobunolol is combined with Dinutuximab.Approved
DipyridamoleDipyridamole may increase the bradycardic activities of Levobunolol.Approved
DisopyramideDisopyramide may increase the bradycardic activities of Levobunolol.Approved
DonepezilDonepezil may increase the bradycardic activities of Levobunolol.Approved
DoxazosinThe risk or severity of adverse effects can be increased when Doxazosin is combined with Levobunolol.Approved
DronedaroneDronedarone may increase the bradycardic activities of Levobunolol.Approved
DroxicamDroxicam may decrease the antihypertensive activities of Levobunolol.Approved
DuloxetineLevobunolol may increase the orthostatic hypotensive activities of Duloxetine.Approved
DuvelisibDuvelisib may decrease the antihypertensive activities of Levobunolol.Investigational
E6201E6201 may decrease the antihypertensive activities of Levobunolol.Investigational
EbselenEbselen may decrease the antihypertensive activities of Levobunolol.Investigational
EchothiophateEchothiophate may increase the bradycardic activities of Levobunolol.Approved
EdrophoniumEdrophonium may increase the bradycardic activities of Levobunolol.Approved
EfonidipineThe risk or severity of adverse effects can be increased when Levobunolol is combined with Efonidipine.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Levobunolol is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Levobunolol.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Levobunolol is combined with Enalaprilat.Approved
EPIBATIDINEThe risk or severity of adverse effects can be increased when Levobunolol is combined with EPIBATIDINE.Experimental
EpirizoleEpirizole may decrease the antihypertensive activities of Levobunolol.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Eplerenone is combined with Levobunolol.Approved
EpoprostenolThe risk or severity of adverse effects can be increased when Levobunolol is combined with Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Levobunolol.Approved
Ergoloid mesylateLevobunolol may increase the vasoconstricting activities of Ergoloid mesylate.Approved
ErgonovineLevobunolol may increase the vasoconstricting activities of Ergonovine.Approved
ErgotamineLevobunolol may increase the vasoconstricting activities of Ergotamine.Approved
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Levobunolol.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Levobunolol.Approved
EtanerceptEtanercept may decrease the antihypertensive activities of Levobunolol.Approved, Investigational
EtodolacEtodolac may decrease the antihypertensive activities of Levobunolol.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may decrease the antihypertensive activities of Levobunolol.Approved
EtoperidoneThe serum concentration of Levobunolol can be increased when it is combined with Etoperidone.Approved
EtoricoxibEtoricoxib may decrease the antihypertensive activities of Levobunolol.Approved, Investigational
Evening primrose oilEvening primrose oil may decrease the antihypertensive activities of Levobunolol.Approved
exisulindexisulind may decrease the antihypertensive activities of Levobunolol.Investigational
FelodipineThe risk or severity of adverse effects can be increased when Felodipine is combined with Levobunolol.Approved, Investigational
FenbufenFenbufen may decrease the antihypertensive activities of Levobunolol.Approved
FenoldopamThe risk or severity of adverse effects can be increased when Levobunolol is combined with Fenoldopam.Approved
FenoprofenFenoprofen may decrease the antihypertensive activities of Levobunolol.Approved
FentanylFentanyl may increase the bradycardic activities of Levobunolol.Approved, Illicit, Investigational, Vet Approved
FenthionFenthion may increase the bradycardic activities of Levobunolol.Vet Approved
FimasartanThe risk or severity of adverse effects can be increased when Levobunolol is combined with Fimasartan.Approved
FingolimodLevobunolol may increase the bradycardic activities of Fingolimod.Approved, Investigational
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Levobunolol.Approved, Withdrawn
FlunixinFlunixin may decrease the antihypertensive activities of Levobunolol.Vet Approved
FluoxetineThe serum concentration of Levobunolol can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FluphenazineFluphenazine may increase the hypotensive activities of Levobunolol.Approved
FlurbiprofenFlurbiprofen may decrease the antihypertensive activities of Levobunolol.Approved, Investigational
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Levobunolol.Approved
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Levobunolol.Approved, Vet Approved
GalantamineGalantamine may increase the bradycardic activities of Levobunolol.Approved
Gallamine TriethiodideGallamine Triethiodide may increase the bradycardic activities of Levobunolol.Approved
Ginkgo bilobaGinkgo biloba may increase the bradycardic activities of Levobunolol.Approved, Nutraceutical
GlibornurideLevobunolol may increase the hypoglycemic activities of Glibornuride.Withdrawn
GliclazideLevobunolol may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideLevobunolol may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideLevobunolol may increase the hypoglycemic activities of Glipizide.Approved
GliquidoneLevobunolol may increase the hypoglycemic activities of Gliquidone.Approved
GlisoxepideLevobunolol may increase the hypoglycemic activities of Glisoxepide.Approved
GlyburideLevobunolol may increase the hypoglycemic activities of Glyburide.Approved
GTS-21The risk or severity of adverse effects can be increased when Levobunolol is combined with GTS-21.Investigational
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Levobunolol.Approved, Investigational
HalothaneThe risk or severity of adverse effects can be increased when Levobunolol is combined with Halothane.Approved, Vet Approved
HexobarbitalHexobarbital may increase the hypotensive activities of Levobunolol.Approved
HigenamineHigenamine may decrease the antihypertensive activities of Levobunolol.Investigational
HMPL-004HMPL-004 may decrease the antihypertensive activities of Levobunolol.Investigational
Huperzine AHuperzine A may increase the bradycardic activities of Levobunolol.Investigational
HydralazineThe risk or severity of adverse effects can be increased when Levobunolol is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Levobunolol.Approved, Vet Approved
HydroflumethiazideThe risk or severity of adverse effects can be increased when Levobunolol is combined with Hydroflumethiazide.Approved
HydroxychloroquineThe metabolism of Levobunolol can be decreased when combined with Hydroxychloroquine.Approved
IbuprofenIbuprofen may decrease the antihypertensive activities of Levobunolol.Approved
IbuproxamIbuproxam may decrease the antihypertensive activities of Levobunolol.Withdrawn
IcatibantIcatibant may decrease the antihypertensive activities of Levobunolol.Approved
IloprostThe risk or severity of adverse effects can be increased when Levobunolol is combined with Iloprost.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Levobunolol is combined with Imidapril.Investigational
ImipramineThe risk or severity of adverse effects can be increased when Levobunolol is combined with Imipramine.Approved
IndalpineThe serum concentration of Levobunolol can be increased when it is combined with Indalpine.Investigational, Withdrawn
IndapamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Levobunolol.Approved
IndomethacinIndomethacin may decrease the antihypertensive activities of Levobunolol.Approved, Investigational
IndoprofenIndoprofen may decrease the antihypertensive activities of Levobunolol.Withdrawn
IndoraminThe risk or severity of adverse effects can be increased when Levobunolol is combined with Indoramin.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Levobunolol.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Levobunolol is combined with Isocarboxazid.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Levobunolol is combined with Isoflurane.Approved, Vet Approved
IsoflurophateIsoflurophate may increase the bradycardic activities of Levobunolol.Approved, Withdrawn
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Levobunolol.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Levobunolol.Approved
IsoxicamIsoxicam may decrease the antihypertensive activities of Levobunolol.Withdrawn
IsoxsuprineThe risk or severity of adverse effects can be increased when Levobunolol is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Levobunolol.Approved
IvabradineLevobunolol may increase the bradycardic activities of Ivabradine.Approved
KebuzoneKebuzone may decrease the antihypertensive activities of Levobunolol.Experimental
KetoprofenKetoprofen may decrease the antihypertensive activities of Levobunolol.Approved, Vet Approved
KetorolacKetorolac may decrease the antihypertensive activities of Levobunolol.Approved
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with Levobunolol.Approved
LacidipineThe risk or severity of adverse effects can be increased when Levobunolol is combined with Lacidipine.Approved
LacosamideLevobunolol may increase the atrioventricular blocking (AV block) activities of Lacosamide.Approved
LanreotideLevobunolol may increase the bradycardic activities of Lanreotide.Approved
LeflunomideLeflunomide may decrease the antihypertensive activities of Levobunolol.Approved, Investigational
LercanidipineThe risk or severity of adverse effects can be increased when Levobunolol is combined with Lercanidipine.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobunolol is combined with Levobupivacaine.Approved
LevodopaLevobunolol may increase the orthostatic hypotensive activities of Levodopa.Approved
LevomilnacipranThe serum concentration of Levobunolol can be increased when it is combined with Levomilnacipran.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Levobunolol is combined with Levosimendan.Approved, Investigational
LidocaineThe serum concentration of Lidocaine can be increased when it is combined with Levobunolol.Approved, Vet Approved
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Levobunolol.Approved, Investigational
LisofyllineLisofylline may decrease the antihypertensive activities of Levobunolol.Investigational
LobelineThe risk or severity of adverse effects can be increased when Levobunolol is combined with Lobeline.Investigational
LofexidineThe risk or severity of adverse effects can be increased when Levobunolol is combined with Lofexidine.Approved, Investigational
LornoxicamLornoxicam may decrease the antihypertensive activities of Levobunolol.Approved
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Levobunolol.Approved
LoxoprofenLoxoprofen may decrease the antihypertensive activities of Levobunolol.Approved
LucinactantLevobunolol may increase the bradycardic activities of Lucinactant.Approved
LumiracoxibLumiracoxib may decrease the antihypertensive activities of Levobunolol.Approved, Investigational
Magnesium salicylateMagnesium salicylate may decrease the antihypertensive activities of Levobunolol.Approved
MalathionMalathion may increase the bradycardic activities of Levobunolol.Approved, Investigational
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Levobunolol.Approved, Investigational
MasoprocolMasoprocol may decrease the antihypertensive activities of Levobunolol.Approved
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Levobunolol.Approved
Meclofenamic acidMeclofenamic acid may decrease the antihypertensive activities of Levobunolol.Approved, Vet Approved
Mefenamic acidMefenamic acid may decrease the antihypertensive activities of Levobunolol.Approved
MefloquineMefloquine may increase the bradycardic activities of Levobunolol.Approved
MeloxicamMeloxicam may decrease the antihypertensive activities of Levobunolol.Approved, Vet Approved
MemantineMemantine may increase the bradycardic activities of Levobunolol.Approved, Investigational
MepivacaineThe serum concentration of Mepivacaine can be increased when it is combined with Levobunolol.Approved, Vet Approved
MesalazineMesalazine may decrease the antihypertensive activities of Levobunolol.Approved
MesoridazineMesoridazine may increase the hypotensive activities of Levobunolol.Approved
MetamizoleMetamizole may decrease the antihypertensive activities of Levobunolol.Withdrawn
MethacholineThe risk or severity of adverse effects can be increased when Levobunolol is combined with Methacholine.Approved
Methanesulfonyl FluorideMethanesulfonyl Fluoride may increase the bradycardic activities of Levobunolol.Investigational
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Levobunolol.Approved
MethohexitalMethohexital may increase the hypotensive activities of Levobunolol.Approved
MethotrimeprazineMethotrimeprazine may increase the hypotensive activities of Levobunolol.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Levobunolol.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Methyldopa is combined with Levobunolol.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Levobunolol.Investigational
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Levobunolol.Approved
MetipranololThe risk or severity of adverse effects can be increased when Levobunolol is combined with Metipranolol.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Levobunolol.Approved
MetoprololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Levobunolol.Approved, Investigational
MidodrineLevobunolol may increase the bradycardic activities of Midodrine.Approved
MilnacipranThe serum concentration of Levobunolol can be increased when it is combined with Milnacipran.Approved
MinaprineMinaprine may increase the bradycardic activities of Levobunolol.Approved
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Levobunolol.Approved
MizoribineMizoribine may decrease the antihypertensive activities of Levobunolol.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Levobunolol.Approved
MoricizineMoricizine may increase the hypotensive activities of Levobunolol.Approved, Withdrawn
MorphineThe risk or severity of adverse effects can be increased when Levobunolol is combined with Morphine.Approved, Investigational
MoxonidineThe risk or severity of adverse effects can be increased when Levobunolol is combined with Moxonidine.Approved
Mycophenolate mofetilMycophenolate mofetil may decrease the antihypertensive activities of Levobunolol.Approved, Investigational
Mycophenolic acidMycophenolic acid may decrease the antihypertensive activities of Levobunolol.Approved
NabiloneThe risk or severity of adverse effects can be increased when Levobunolol is combined with Nabilone.Approved, Investigational
NabumetoneNabumetone may decrease the antihypertensive activities of Levobunolol.Approved
NadololThe risk or severity of adverse effects can be increased when Nadolol is combined with Levobunolol.Approved
NafamostatNafamostat may decrease the antihypertensive activities of Levobunolol.Investigational
NaftifineNaftifine may decrease the antihypertensive activities of Levobunolol.Approved
NaproxenNaproxen may decrease the antihypertensive activities of Levobunolol.Approved, Vet Approved
NCX 4016NCX 4016 may decrease the antihypertensive activities of Levobunolol.Investigational
NebivololThe risk or severity of adverse effects can be increased when Levobunolol is combined with Nebivolol.Approved, Investigational
NefazodoneThe serum concentration of Levobunolol can be increased when it is combined with Nefazodone.Approved, Withdrawn
NeostigmineNeostigmine may increase the bradycardic activities of Levobunolol.Approved, Vet Approved
NepafenacNepafenac may decrease the antihypertensive activities of Levobunolol.Approved
NesiritideThe risk or severity of adverse effects can be increased when Levobunolol is combined with Nesiritide.Approved, Investigational
NicardipineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Levobunolol.Approved
NicorandilNicorandil may increase the hypotensive activities of Levobunolol.Approved
NicotineThe risk or severity of adverse effects can be increased when Levobunolol is combined with Nicotine.Approved
Nicotine bitartrateThe risk or severity of adverse effects can be increased when Levobunolol is combined with Nicotine bitartrate.Approved
NifedipineNifedipine may increase the hypotensive activities of Levobunolol.Approved
Niflumic AcidNiflumic Acid may decrease the antihypertensive activities of Levobunolol.Approved
NilvadipineThe risk or severity of adverse effects can be increased when Levobunolol is combined with Nilvadipine.Approved
NimesulideNimesulide may decrease the antihypertensive activities of Levobunolol.Approved, Withdrawn
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Levobunolol.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Levobunolol.Approved
NitrendipineThe risk or severity of adverse effects can be increased when Levobunolol is combined with Nitrendipine.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Levobunolol is combined with Nitric Oxide.Approved
NitroaspirinNitroaspirin may decrease the antihypertensive activities of Levobunolol.Investigational
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Levobunolol.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Levobunolol.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Levobunolol is combined with Obinutuzumab.Approved
OctreotideOctreotide may increase the bradycardic activities of Levobunolol.Approved, Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Levobunolol.Approved, Investigational
OlopatadineOlopatadine may decrease the antihypertensive activities of Levobunolol.Approved
OlsalazineOlsalazine may decrease the antihypertensive activities of Levobunolol.Approved
OrgoteinOrgotein may decrease the antihypertensive activities of Levobunolol.Vet Approved
OuabainLevobunolol may increase the bradycardic activities of Ouabain.Approved
OxaprozinOxaprozin may decrease the antihypertensive activities of Levobunolol.Approved
OxprenololThe risk or severity of adverse effects can be increased when Levobunolol is combined with Oxprenolol.Approved
OxyphenbutazoneOxyphenbutazone may decrease the antihypertensive activities of Levobunolol.Withdrawn
PaclitaxelThe risk or severity of adverse effects can be increased when Levobunolol is combined with Paclitaxel.Approved, Vet Approved
PapaverineThe risk or severity of adverse effects can be increased when Papaverine is combined with Levobunolol.Approved
ParecoxibParecoxib may decrease the antihypertensive activities of Levobunolol.Approved
ParoxetineThe serum concentration of Levobunolol can be increased when it is combined with Paroxetine.Approved, Investigational
PasireotideLevobunolol may increase the bradycardic activities of Pasireotide.Approved
PenbutololThe risk or severity of adverse effects can be increased when Levobunolol is combined with Penbutolol.Approved, Investigational
PentobarbitalPentobarbital may increase the hypotensive activities of Levobunolol.Approved, Vet Approved
PerazinePerazine may increase the hypotensive activities of Levobunolol.Investigational
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Levobunolol.Approved
PerphenazinePerphenazine may increase the hypotensive activities of Levobunolol.Approved
PhenelzineThe risk or severity of adverse effects can be increased when Levobunolol is combined with Phenelzine.Approved
PhenobarbitalPhenobarbital may increase the hypotensive activities of Levobunolol.Approved
PhenoxybenzamineThe risk or severity of adverse effects can be increased when Levobunolol is combined with Phenoxybenzamine.Approved
PhentolamineThe risk or severity of adverse effects can be increased when Levobunolol is combined with Phentolamine.Approved
PhenylbutazonePhenylbutazone may decrease the antihypertensive activities of Levobunolol.Approved, Vet Approved
PhysostigminePhysostigmine may increase the bradycardic activities of Levobunolol.Approved
PilocarpineThe risk or severity of adverse effects can be increased when Levobunolol is combined with Pilocarpine.Approved
PimecrolimusPimecrolimus may decrease the antihypertensive activities of Levobunolol.Approved, Investigational
PindololThe risk or severity of adverse effects can be increased when Pindolol is combined with Levobunolol.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Levobunolol is combined with Pipamperone.Approved
PirfenidonePirfenidone may decrease the antihypertensive activities of Levobunolol.Investigational
PiroxicamPiroxicam may decrease the antihypertensive activities of Levobunolol.Approved, Investigational
Poractant alfaLevobunolol may increase the bradycardic activities of Poractant alfa.Approved
PramipexoleThe risk or severity of adverse effects can be increased when Levobunolol is combined with Pramipexole.Approved, Investigational
PrazosinThe risk or severity of adverse effects can be increased when Prazosin is combined with Levobunolol.Approved
PrimaquineThe metabolism of Levobunolol can be decreased when combined with Primaquine.Approved
PrimidonePrimidone may increase the hypotensive activities of Levobunolol.Approved, Vet Approved
ProchlorperazineProchlorperazine may increase the hypotensive activities of Levobunolol.Approved, Vet Approved
PromazinePromazine may increase the hypotensive activities of Levobunolol.Approved, Vet Approved
PromethazinePromethazine may increase the hypotensive activities of Levobunolol.Approved
PropacetamolPropacetamol may decrease the antihypertensive activities of Levobunolol.Approved
PropafenoneThe serum concentration of Levobunolol can be increased when it is combined with Propafenone.Approved
PropiopromazinePropiopromazine may increase the hypotensive activities of Levobunolol.Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Levobunolol is combined with Propofol.Approved, Investigational, Vet Approved
PropranololThe risk or severity of adverse effects can be increased when Propranolol is combined with Levobunolol.Approved, Investigational
PTC299PTC299 may decrease the antihypertensive activities of Levobunolol.Investigational
PyridostigminePyridostigmine may increase the bradycardic activities of Levobunolol.Approved
QuetiapineThe risk or severity of adverse effects can be increased when Levobunolol is combined with Quetiapine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Levobunolol.Approved, Investigational
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Levobunolol.Approved
RasagilineThe risk or severity of adverse effects can be increased when Levobunolol is combined with Rasagiline.Approved
RegorafenibRegorafenib may increase the bradycardic activities of Levobunolol.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Levobunolol is combined with Remifentanil.Approved
ReserpineReserpine may increase the hypotensive activities of Levobunolol.Approved
ResveratrolResveratrol may decrease the antihypertensive activities of Levobunolol.Experimental, Investigational
RifampicinThe serum concentration of Levobunolol can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Levobunolol can be decreased when it is combined with Rifapentine.Approved
RiociguatThe risk or severity of adverse effects can be increased when Levobunolol is combined with Riociguat.Approved
RisperidoneLevobunolol may increase the hypotensive activities of Risperidone.Approved, Investigational
RivastigmineRivastigmine may increase the bradycardic activities of Levobunolol.Approved, Investigational
RofecoxibRofecoxib may decrease the antihypertensive activities of Levobunolol.Investigational, Withdrawn
RopiniroleThe risk or severity of adverse effects can be increased when Levobunolol is combined with Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Levobunolol is combined with Ropivacaine.Approved
RotigotineThe risk or severity of adverse effects can be increased when Levobunolol is combined with Rotigotine.Approved
RuxolitinibRuxolitinib may increase the bradycardic activities of Levobunolol.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Levobunolol is combined with Sacubitril.Approved
SalicylamideSalicylamide may decrease the antihypertensive activities of Levobunolol.Approved
Salicylic acidSalicylic acid may decrease the antihypertensive activities of Levobunolol.Approved, Vet Approved
SalsalateSalsalate may decrease the antihypertensive activities of Levobunolol.Approved
SecobarbitalSecobarbital may increase the hypotensive activities of Levobunolol.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Levobunolol is combined with Selegiline.Approved, Investigational, Vet Approved
SeratrodastSeratrodast may decrease the antihypertensive activities of Levobunolol.Approved, Investigational
SertralineThe serum concentration of Levobunolol can be increased when it is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Levobunolol is combined with Sevoflurane.Approved, Vet Approved
Sodium NitriteThe risk or severity of adverse effects can be increased when Levobunolol is combined with Sodium Nitrite.Approved
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Levobunolol.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Levobunolol.Approved
SRT501SRT501 may decrease the antihypertensive activities of Levobunolol.Investigational
StreptokinaseThe risk or severity of adverse effects can be increased when Levobunolol is combined with Streptokinase.Approved
SufentanilSufentanil may increase the bradycardic activities of Levobunolol.Approved, Investigational
SulfasalazineSulfasalazine may decrease the antihypertensive activities of Levobunolol.Approved
SulindacSulindac may decrease the antihypertensive activities of Levobunolol.Approved
SuprofenSuprofen may decrease the antihypertensive activities of Levobunolol.Approved, Withdrawn
TacrineTacrine may increase the bradycardic activities of Levobunolol.Withdrawn
TamsulosinThe risk or severity of adverse effects can be increased when Levobunolol is combined with Tamsulosin.Approved, Investigational
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Levobunolol.Approved, Investigational
TenoxicamTenoxicam may decrease the antihypertensive activities of Levobunolol.Approved
TepoxalinTepoxalin may decrease the antihypertensive activities of Levobunolol.Vet Approved
TerazosinThe risk or severity of adverse effects can be increased when Terazosin is combined with Levobunolol.Approved
TeriflunomideTeriflunomide may decrease the antihypertensive activities of Levobunolol.Approved
ThalidomideThe risk or severity of adverse effects can be increased when Levobunolol is combined with Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThiamylal may increase the hypotensive activities of Levobunolol.Approved, Vet Approved
ThiethylperazineThiethylperazine may increase the hypotensive activities of Levobunolol.Withdrawn
ThiopentalThiopental may increase the hypotensive activities of Levobunolol.Approved, Vet Approved
ThioridazineThioridazine may increase the hypotensive activities of Levobunolol.Approved
Tiaprofenic acidTiaprofenic acid may decrease the antihypertensive activities of Levobunolol.Approved
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Levobunolol.Approved
TinoridineTinoridine may decrease the antihypertensive activities of Levobunolol.Investigational
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Levobunolol.Approved
TofacitinibTofacitinib may increase the bradycardic activities of Levobunolol.Approved, Investigational
TolazamideLevobunolol may increase the hypoglycemic activities of Tolazamide.Approved
TolazolineThe risk or severity of adverse effects can be increased when Levobunolol is combined with Tolazoline.Approved, Vet Approved
TolbutamideLevobunolol may increase the hypoglycemic activities of Tolbutamide.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Levobunolol is combined with Tolcapone.Approved, Withdrawn
Tolfenamic AcidTolfenamic Acid may decrease the antihypertensive activities of Levobunolol.Approved
TolmetinTolmetin may decrease the antihypertensive activities of Levobunolol.Approved
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Levobunolol.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Levobunolol.Approved
TranilastTranilast may decrease the antihypertensive activities of Levobunolol.Approved, Investigational
TranylcypromineThe risk or severity of adverse effects can be increased when Levobunolol is combined with Tranylcypromine.Approved
TretinoinThe risk or severity of adverse effects can be increased when Levobunolol is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Levobunolol.Approved
TrichlorfonTrichlorfon may increase the bradycardic activities of Levobunolol.Vet Approved
TrifluoperazineTrifluoperazine may increase the hypotensive activities of Levobunolol.Approved
TriflupromazineTriflupromazine may increase the hypotensive activities of Levobunolol.Approved, Vet Approved
Trisalicylate-cholineTrisalicylate-choline may decrease the antihypertensive activities of Levobunolol.Approved
TubocurarineTubocurarine may increase the bradycardic activities of Levobunolol.Approved
ValdecoxibValdecoxib may decrease the antihypertensive activities of Levobunolol.Investigational, Withdrawn
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Levobunolol.Approved, Investigational
VareniclineThe risk or severity of adverse effects can be increased when Levobunolol is combined with Varenicline.Approved, Investigational
VenlafaxineThe serum concentration of Levobunolol can be increased when it is combined with Venlafaxine.Approved
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Levobunolol.Approved
ZaltoprofenZaltoprofen may decrease the antihypertensive activities of Levobunolol.Approved
ZileutonZileuton may decrease the antihypertensive activities of Levobunolol.Approved, Investigational, Withdrawn
ZimelidineThe serum concentration of Levobunolol can be increased when it is combined with Zimelidine.Withdrawn
ZomepiracZomepirac may decrease the antihypertensive activities of Levobunolol.Withdrawn
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General References
  1. Ishibashi T, Yokoi N, Kinoshita S: Comparison of the effects of topical levobunolol and timolol solution on the human ocular surface. Cornea. 2003 Nov;22(8):709-15. [PubMed:14576520 ]
  2. Ogasawara H, Yoshida A, Fujio N, Konno S, Ishiko S: [Effect of topical levobunolol on retinal, optic nerve head, and choroidal circulation in normal volunteers]. Nippon Ganka Gakkai Zasshi. 1999 Jul;103(7):544-50. [PubMed:10443129 ]
  3. Leung M, Grunwald JE: Short-term effects of topical levobunolol on the human retinal circulation. Eye (Lond). 1997;11 ( Pt 3):371-6. [PubMed:9373479 ]
  4. Dong Y, Ishikawa H, Wu Y, Yoshitomi T: Vasodilatory mechanism of levobunolol on vascular smooth muscle cells. Exp Eye Res. 2007 Jun;84(6):1039-46. Epub 2007 Jan 27. [PubMed:17459374 ]
  5. Gonzalez JP, Clissold SP: Ocular levobunolol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs. 1987 Dec;34(6):648-61. [PubMed:2892662 ]
  6. Lesar TS: Comparison of ophthalmic beta-blocking agents. Clin Pharm. 1987 Jun;6(6):451-63. [PubMed:2891463 ]
  7. Novack GD: Levobunolol for the long-term treatment of glaucoma. Gen Pharmacol. 1986;17(4):373-7. [PubMed:3019819 ]
External Links
ATC CodesS01ED03
AHFS Codes
  • 52:92.00
PDB EntriesNot Available
FDA labelDownload (850 KB)
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9923
Blood Brain Barrier-0.8738
Caco-2 permeable-0.6105
P-glycoprotein substrateSubstrate0.8227
P-glycoprotein inhibitor IInhibitor0.5712
P-glycoprotein inhibitor IINon-inhibitor0.5691
Renal organic cation transporterNon-inhibitor0.8179
CYP450 2C9 substrateNon-substrate0.7696
CYP450 2D6 substrateSubstrate0.8547
CYP450 3A4 substrateNon-substrate0.5554
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8378
Ames testNon AMES toxic0.8825
CarcinogenicityNon-carcinogens0.9039
BiodegradationNot ready biodegradable0.9972
Rat acute toxicity2.1253 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9613
hERG inhibition (predictor II)Inhibitor0.593
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
LiquidOphthalmic0.5 %
LiquidOphthalmic5 mg
LiquidOphthalmic0.25 %
SolutionOphthalmic5 mg/mL
Solution / dropsOphthalmic2.5 mg/mL
Solution / dropsOphthalmic5 mg/mL
LiquidOphthalmic0.50 %
LiquidOphthalmic
SolutionOphthalmic0.25 %
SolutionOphthalmic0.5 %
Prices
Unit descriptionCostUnit
Levobunolol HCl 0.5% Solution 15ml Bottle50.25USD bottle
Levobunolol HCl 0.5% Solution 10ml Bottle33.58USD bottle
Levobunolol HCl 0.25% Solution 10ml Bottle32.59USD bottle
Levobunolol HCl 0.5% Solution 5ml Bottle17.26USD bottle
Levobunolol HCl 0.25% Solution 5ml Bottle16.45USD bottle
Betagan 0.5% Solution6.39USD ml
Betagan 0.5% eye drops6.1USD ml
Betagan 0.25% eye drops4.9USD ml
Betagan 0.5 % Solution3.7USD ml
Levobunolol 0.5% eye drops3.24USD ml
Levobunolol 0.25% eye drops2.83USD ml
Pms-Levobunolol 0.5 % Solution1.63USD ml
Ratio-Levobunolol 0.5 % Solution1.63USD ml
Sandoz Levobunolol 0.5 % Solution1.63USD ml
Ratio-Levobunolol 0.25 % Solution1.23USD ml
Sandoz Levobunolol 0.25 % Solution1.23USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point209-211 °CNot Available
logP2.40HANSCH,C ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.251 mg/mLALOGPS
logP2.06ALOGPS
logP2.18ChemAxon
logS-3.1ALOGPS
pKa (Strongest Acidic)14.09ChemAxon
pKa (Strongest Basic)9.66ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area58.56 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity83.28 m3·mol-1ChemAxon
Polarizability33.38 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as tetralins. These are polycyclic aromatic compounds containing a tetralin moiety, which consists of a benzene fused to a cyclohexane.
KingdomOrganic compounds
Super ClassBenzenoids
ClassTetralins
Sub ClassNot Available
Direct ParentTetralins
Alternative Parents
Substituents
  • Tetralin
  • Aryl alkyl ketone
  • Aryl ketone
  • Alkyl aryl ether
  • Secondary alcohol
  • Ketone
  • 1,2-aminoalcohol
  • Secondary amine
  • Ether
  • Secondary aliphatic amine
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Alcohol
  • Aromatic homopolycyclic compound
Molecular FrameworkAromatic homopolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Receptor signaling protein activity
Specific Function:
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately equal affinity. Mediates Ras activation through G(s)-alpha- and cAMP-mediated signaling.
Gene Name:
ADRB1
Uniprot ID:
P08588
Molecular Weight:
51322.1 Da
References
  1. Lesar TS: Comparison of ophthalmic beta-blocking agents. Clin Pharm. 1987 Jun;6(6):451-63. [PubMed:2891463 ]
  2. Harris A, Malinovsky V, Martin B: Correlates of acute exercise-induced ocular hypotension. Invest Ophthalmol Vis Sci. 1994 Oct;35(11):3852-7. [PubMed:7928182 ]
  3. Chidlow G, Melena J, Osborne NN: Betaxolol, a beta(1)-adrenoceptor antagonist, reduces Na(+) influx into cortical synaptosomes by direct interaction with Na(+) channels: comparison with other beta-adrenoceptor antagonists. Br J Pharmacol. 2000 Jun;130(4):759-66. [PubMed:10864881 ]
  4. Sharif NA, Xu SX, Crider JY, McLaughlin M, Davis TL: Levobetaxolol (Betaxon) and other beta-adrenergic antagonists: preclinical pharmacology, IOP-lowering activity and sites of action in human eyes. J Ocul Pharmacol Ther. 2001 Aug;17(4):305-17. [PubMed:11572462 ]
  5. Brooks AM, Gillies WE: Ocular beta-blockers in glaucoma management. Clinical pharmacological aspects. Drugs Aging. 1992 May-Jun;2(3):208-21. [PubMed:1351412 ]
  6. Gonzalez JP, Clissold SP: Ocular levobunolol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs. 1987 Dec;34(6):648-61. [PubMed:2892662 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Protein homodimerization activity
Specific Function:
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately 30-fold greater affinity than it does norepinephrine.
Gene Name:
ADRB2
Uniprot ID:
P07550
Molecular Weight:
46458.32 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Quast U, Vollmer KO: Binding of beta-adrenoceptor antagonists to rat and rabbit lung: special reference to levobunolol. Arzneimittelforschung. 1984;34(5):579-84. [PubMed:6147147 ]
  3. Sharif NA, Xu SX, Crider JY, McLaughlin M, Davis TL: Levobetaxolol (Betaxon) and other beta-adrenergic antagonists: preclinical pharmacology, IOP-lowering activity and sites of action in human eyes. J Ocul Pharmacol Ther. 2001 Aug;17(4):305-17. [PubMed:11572462 ]
  4. Harris A, Malinovsky V, Martin B: Correlates of acute exercise-induced ocular hypotension. Invest Ophthalmol Vis Sci. 1994 Oct;35(11):3852-7. [PubMed:7928182 ]
  5. Brooks AM, Gillies WE: Ocular beta-blockers in glaucoma management. Clinical pharmacological aspects. Drugs Aging. 1992 May-Jun;2(3):208-21. [PubMed:1351412 ]
  6. Gonzalez JP, Clissold SP: Ocular levobunolol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs. 1987 Dec;34(6):648-61. [PubMed:2892662 ]
  7. Lesar TS: Comparison of ophthalmic beta-blocking agents. Clin Pharm. 1987 Jun;6(6):451-63. [PubMed:2891463 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23